In 1997, Xcelom’s founder was the first to report the existence of cell-free fetal DNA in the blood of pregnant women. After years of dedicated research, methods for the non-invasive screening of fetal chromosomal aneuploidies, were successfully achieved. The clinical performances of the test approaches developed by the research team were subsequently validated and confirmed by a number of international research groups and this formed the basis for many of the non-invasive prenatal testing protocols adopted for clinical use worldwide today. Xcelom is the only licensee of the CUHK technologies in Hong Kong to provide the test.
Best SME Award 2021 - Xcelom Limited
Exclusive Licencee of Non-Invasive Prenatal Testing (NIPT) Service in Hong Kong
Health Partnership Awards 2021 - Outstanding Innovative Health Assessment Solutions - Xcelom Limited
CORPHUB An interview with the CEO of Xcelom, Alex Wong
InvestHK Xcelom Limited
Pharma boardroom Alex Wong – CEO, Xcelom
"HSBC x HKET Innovative Business Award 2019" Innovative SME - Xcelom Limited
HKTDC: The Challenges Facing Hong Kong Start-ups: Go-to-market
